Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the
treatment of B cell malignancies. However, further refinement is needed to this class of agents, …

3-(S)-Pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid (5e) and 3-(S)-(methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic
acid (5f) were …

SF0166, a small-molecule α v β 3 antagonist, has physiochemical properties that allow
distribution to the posterior segment of the eye after topical administration in an ophthalmic …

11β-Hydroxysteroid dehydrogenase-1 (11βHSD1) is a therapeutic target for Type 2 diabetes
that has stimulated the interest of many pharmaceutical companies. Mounting evidence …

Potent non-peptidic α v β 3 antagonists have been prepared where deletion of an amide
bond from an earlier series of linear RGD-mimetics provides a novel series of chain-shortened …

A series of α v β 3 receptor antagonists lacking the amide bond of previously-reported ‘chain-shortened’
compounds is described. Replacement of the lone amide bond with two …

Potent non-peptidic α v β 3 antagonists have been prepared incorporating various β-amino
acids as aspartic acid mimetics. Modification of the β-alanine 3-substituents alters the …

The nonpeptide platelet glycoprotein IIb/IIIa antagonist, L-738,167, was characterized in
dog and nonhuman primate. In an anesthetized canine model of coronary artery electrolytic …

Background A conscious dog model of left circumflex coronary artery electrolytic injury was
used to assess the oral antithrombotic efficacy of L-738,167, a potent nonpeptide antagonist …

l-738,167 is a potent and long-acting fibrinogen receptor antagonist and may be useful for
treatment of chronic thrombotic occlusive disorders. The purposes of this study were to …